Biovica, a company specializing in blood-based cancer monitoring, today announced that it has received a new work order from a current customer, one of the world’s leading pharmaceutical companies with a strong oncology pipeline. This marks the ninth work order received from the same customer, further strengthening the ongoing collaboration.
The work order covers DiviTum® TKa testing services for a clinical breast cancer study evaluating a next-generation CDK inhibitor in combination with endocrine therapy. The study includes serial TKa testing over a period of up to four years, supporting longitudinal monitoring of tumor proliferation dynamics and biological treatment effect.
Testing will be performed through Biovica’s CLIA-certified laboratory in San Diego, California, and is expected to be initiated in October 2026. The order value to Biovica is approximately SEK 1.7 million, including sample testing and related laboratory services.
“Receiving a ninth work order from the same customer is an important confirmation of both the commercial value and scientific relevance of DiviTum® TKa in oncology drug development. The order further strengthens our Pharma Services business and reinforces the potential of DiviTum® TKa as a functional biomarker in drug development,” said Theis Kipling, CEO of Biovica.